Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects With Moderately to Severely Active Ulcerative Colitis

NCT04130919 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT04130919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04130919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Terminated
Start date
December 20, 2019
Completion date
December 14, 2021
Enrollment
19 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis